ADI Stock Recent News
ADI LATEST HEADLINES
Citi is keeping an eye on weak demand in the PC and auto markets.
CodeFusion Studio™ and ADI's new Developer Portal are inaugural components of a new suite of developer-centric offerings, which unite cross-device, cross-market hardware, software and services Also included is the ADI Assure™ Trusted Edge Security Architecture, a universal security architecture to deliver more reliable, trustworthy capabilities across the stack Combined, the offerings provide a developer-centric experience that incorporates open-source configuration and profiling tools that are designed to enable faster time to market with enhanced security and reliability WILMINGTON, Mass. , Oct. 7, 2024 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader, today launched a suite of developer-centric offerings that unite cross-device, cross-market hardware, software and services to help customers deliver innovations for the Intelligent Edge with enhanced speed and security.
Analog Devices (ADI) concluded the recent trading session at $228.23, signifying a +0.74% move from its prior day's close.
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. “The favorable safety profile, cellular kinetics and B cell depletion in peripheral blood and secondary lymphoid tissue demonstrated with ADI-001 clinical exper.
In the most recent trading session, Analog Devices (ADI) closed at $232.05, indicating a -0.18% shift from the previous trading day.
Analog Devices (ADI) reported earnings 30 days ago. What's next for the stock?
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for autoimmune diseases. Notably, ADI-001 demonstrated robust tissue trafficking resulting in high levels.
Analog Devices' top and bottom lines fell last quarter, but its guidance suggests a turnaround is on the way. The company points out that inventory levels in its end markets are normalizing, and order momentum is picking up.
ADI is benefiting from a strong portfolio and expanding partnerships amid macro headwinds and stiff competition.
Analog Devices, Inc. (NASDAQ:ADI ) Citi's 2024 Global TMT Conference September 4, 2024 1:20 PM ET Company Participants Mike Lucarelli - VP of Finance, IR, FP&A Conference Call Participants Chris Danely - Citi Chris Danely Everyone, I'm Chris Danely, your friendly neighborhood semiconductor analyst here. It's our pleasure next to have one of our topics, Analog Devices.